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Background: The proinflammatory adipokine lipocalin-2 is associated with obesity-related complications, such as heart
failure.
Results: Lipocalin-2 induces cardiomyocyte apoptosis via elevating intracellular iron levels andmediates detrimental effects on
cardiac function.
Conclusion: Lipocalin-2 is an important mediator of cardiac remodeling.
Significance: Regulation of cardiomyocyte apoptosis by lipocalin-2, and the mechanistic role of changes in intracellular iron,
may contribute to the pathogenesis of obesity-related heart failure.
Our objective was to determine whether lipocalin-2 (Lcn2)
regulates cardiomyocyte apoptosis, the mechanisms involved,
and the functional significance. Emerging evidence suggests that
Lcn2 isaproinflammatoryadipokineassociatedwith insulinresist-
anceandobesity-relatedcomplications, suchasheart failure.Here,
we used both primary neonatal rat cardiomyocytes andH9c2 cells
anddemonstrated for the first time that Lcn2directly induced car-
diomyocyte apoptosis, an important component of cardiac remod-
eling leading to heart failure. This was shownby detection ofDNA
fragmentation using TUNEL assay, phosphatidylserine exposure
using flow cytometry to detect annexin V-positive cells, caspase-3
activity using enzymatic assay and immunofluorescence, and
Western blotting for the detection of cleaved caspase-3. We also
observed that Lcn2 caused translocation of the proapoptotic pro-
tein Bax to mitochondria and disruption of mitochondrial mem-
brane potential. Using transient transfection of GFP-Bax, we con-
firmed that Lcn2 induced co-localization of Bax with
MitoTracker dye. Importantly, we used the fluorescent probe
Phen Green SK to demonstrate an increase in intracellular iron in
response to Lcn2, and depleting intracellular iron using an iron
chelator prevented Lcn2-induced cardiomyocyte apoptosis.
Administrationof recombinant Lcn2 tomice for 14days increased
cardiomyocyte apoptosis as well as an acute inflammatory
responsewith compensatory changes in cardiac functional param-
eters. In conclusion, Lcn2-induced cardiomyocyte apoptosis is of
physiological significance and occurs via a mechanism involving
elevated intracellular iron levels and Bax translocation.
Cardiovascular disease is the leading cause of death world-
wide, and individuals with obesity and type 2 diabetes have
an increase in prevalence for cardiovascular morbidity and
mortality (1–3). Heart failure is one example, but mecha-
nisms of obesity- and diabetes-induced heart disease are
multifaceted and remain to be defined clearly (4). A potential
mechanismmay be changes in cardiac remodeling as a result
of altered circulating adipokine and cytokine profiles (5).
Lipocalin-2 (Lcn2,3 also often termed neutrophil gelatinase-
associated lipocalin (NGAL) or oncogene 24p3), is a small,
secreted adipokine and belongs to a diverse family of lipoca-
lins that has the characteristics of binding and transporting
small molecules such as retinoid, fatty acid, steroid, and iron
(6–9). Recent studies show that Lcn2 is a proinflammatory
marker associated with insulin resistance and obesity-re-
lated metabolic disorders (10–14). An increase of Lcn2
expression in adipose tissue is observed in various experi-
mental models of obesity and in obese humans (11, 15, 16). It
was suggested that Lcn2 may mediate the innate immune
responses in the pathogenesis of heart failure (17–20). Lcn2
expression is significantly augmented in patients with coro-
nary heart disease andmyocardial infarction (12, 21). Plasma
Lcn2 was increased after carotid artery injury in rats (22) and
in a heterotopic mouse transplanted heart after ischemia/
reperfusion (23).
Cardiomyocyte apoptosis can play a critical role in the pro-
gression of heart failure. For example, in patients with end-
stage cardiomyopathy in dilated and ischemic heart disease,
hypertrophic heart disease and arrhythmogenic right ventricu-
lar dysplasia, loss of cardiomyocytes due to apoptosis can be
observed that leads to the progression of cardiac dysfunction,
ultimately heart failure (24–27). Lcn2 has been implicated in
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the regulation of cell death in various cell types (28–31),
although whether Lcn2 directly regulates cardiomyocyte apo-
ptosis remains unknown. It has been shown that changes in
intracellular iron content can mediate apoptosis in a variety of
cell types (32–35). Furthermore, iron overload is associated
with cardiomyopathy involving apoptosis and fibrosis leading
to heart failure (36–39). Because Lcn2 has the capability to bind
iron (40–43), we hypothesized that the alteration of intracellu-
lar iron levels is an importantmechanism in Lcn2-induced apo-
ptosis. This study therefore set out to analyze the role of Lcn2
on apoptosis at cellular andmolecular levels, whichmay lead to
better understanding of the pathophysiological role of Lcn2 in
cardiomyopathy.
EXPERIMENTAL PROCEDURES
GeneralMethods—The isolation and primary culture of neo-
natal rat ventricular myocytes were described by us previously
(44). H9c2 cells were cultured as previously described (50).
Wild-type C57BL/6J mice were injected with 200 g/120 l
Lcn2 per mouse daily for up to 14 days. Heart function was
assessed using Vevo2100 system (VisualSonics, Toronto, ON,
Canada) equipped with MS550D transducer. All procedures
were approved by Institut Pasteur Korea Institutional Animal
Care and Use Committee. We produced recombinant mouse
Lcn2 in a bacterial expression system and confirmed it by SDS-
PAGE and mass spectrometry analysis as described previously
(11, 13).
Measures of Apoptosis—Apoptotic cells were quantified by
terminal deoxyribonucleotide transferase-mediated dUTPnick
end-labeling (TUNEL) assay (In Situ Cell Death Detection Kit,
Fluorescein, Roche Diagnostics) following the manufacturer’s
suggested protocol. To quantify the number of apoptotic cells
further, flow cytometry using the FITC Annexin V Apoptosis
Detection Kit I (BD Biosciences) was applied following the
manufacturer’s suggested protocol. Caspase-3 activity was
measured using a Caspase-3 Colorimetric Assay kit (Abcam,
Cambridge, UK) according to the manufacturer’s instruc-
tions. Immunofluorescence staining of endogenous cleaved
caspase-3 and Bax was performed in 96-well or 6-well plates,
respectively. The nuclei were stained with DAPI. Alexa Fluor
488 and 594 secondary antibodies were from Invitrogen, and
rabbit anti-N-terminal Bax (N-20) was from Santa Cruz Bio-
technology. The mitochondrial membrane potential (m)
was determined using MitoShift assay as described previously
(46) by staining of mitochondria with tetramethylrhodamine
ethylester (TMRE) dye (Invitrogen). From in vivo studies, the
heart was then removed and washed with PBS to wash out
blood from the chambers. Thin sections (5 m) from frozen
heart embedded in OCT-compound were prepared. Apoptosis
was assessed by TUNEL assay with an in situ cell death detec-
tion kit as described above and macrophage infiltration by
CD68 staining.
Real-time Analysis of GFP-Bax Translocation—Transient
transfection was performed in 96-well plate. Plasmid pEGFP-
Bax was obtained from Dr. Hsu (Medical University of South
Carolina) (48). Mitochondrial staining was performed using
MitoTrackerMitochondrion-selective Probes (MitoTracker
Red CMXRos; Molecular Probers). After transient transfection
and Lcn2 treatment, cells were incubated with 25 nM Mito-
Tracker dye for 15 min, followed by Hoechst 33342 (Invitro-
gen) staining for another 10 min to stain the nuclei. Bax trans-
location was examined by real-time imaging using LSM5
confocal microscope (Carl ZeissMicrolmaging) with 63 (NA:
1.4) oil-immersion objective.
Western Blot Analysis—Cell lysates were prepared by wash-
ing cell monolayers with PBS and lysing in 1 Cell Lysis buffer
(Cell Signaling Technology) containing phosphatase inhibitors
and protease inhibitormixture (Sigma). Equal protein amounts
were separated by SDS-PAGE and transferred to a polyvi-
nylidene difluoride membrane (Immobilon-P; Millipore
Corp.). The following antibodies were used: rabbit anti-
caspase-3, anti-cleaved caspase-3 (Asp-175), anti-total Bax,
anti--actin, affinity-purified goat anti-rabbit IgG HRP, and
affinity-purified horse anti-mouse IgG HRP (all from Cell Sig-
naling Technology).
Measurement of Intracellular Phen Green SK-chelatable Iron
Level and Image Analysis—Intracellular iron levels were mea-
sured using the fluorescent probe Phen Green SK (PG-SK;
Invitrogen), essentially as described previously (49). For satu-
rating the intracellular iron pool as a positive control, cells were
treated with 100 M ferrous sulfate (FeSO4; Sigma) for 10 min.
As a negative control, cells were incubatedwith a 5mM concen-
tration of the well characterized membrane-permeable iron
chelator 2,2-dipyridyl (2-DPD, Sigma). After washing with
Hanks’ buffered salt solution (HBSS, pH 7.3), the cells were
incubated with 10MPG-SK inHBSS at 37 °C for 10min. After
quickly washing with HBSS, the cells were incubated with
Hoechst 33342 to stain the nuclei for 10 min, followed by 4%
paraformaldehyde fixation. Fluorescence images were then
recorded automatically by a confocal microplate imaging
reader (Evotec Technologies OPERATM; PerkinElmer Life Sci-
ences) at excitation 405 and 488 nm and emission 420 and 520
nm.We segmented cell by cell using in-house software allowing
us to quantify the amount of green fluorescence in the cyto-
plasm. Both nuclei and cytoplasmwere detectedwith intensity-
independent well to well K-mean-based algorithm. The col-
lected data (one point/cell) were analyzed with SpotfireTM
software.
Iron Chelation and Supplementation—To chelate iron, cells
were incubated in serum-free medium for 1 h followed by
pretreatment with different dose of 2-DPD in DMEM/0.2%
FBS for 20 min. For saturating intracellular iron pool as a
positive control, cells were treated with 100 M FeSO4 for
24 h. After treatment of 2 g/ml Lcn2 in DMEM/0.2% FBS in
the presence of 2-DPD for 24 h, the cells were fixed with 4%
paraformaldehyde and permeated with 0.1% Triton X-100.
After blocking with 10% goat serum in PBS for 30 min, cells
were incubated with anti-cleaved caspase-3 (Asp-175, 1:100
dilution) or anti-N terminus of Bax (1:200 dilution) in block-
ing solution for 2 h, followed by incubation with secondary
anti-rabbit Alexa Fluor 488 or 594 antibodies (1:200 dilu-
tion). After the nuclei were stained with Hoechst 33342, the
images were taken by a confocal microscopy. The number of
positive cells over total cells was determined from randomly
selected fields.
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Statistical Analysis—Data from experiments were ex-
pressed as percentage of the value or arbitrary unit from
control versus Lcn2 treatment. Bars in figures represent
mean  S.E. values determined from at least three indepen-
dent samples or experiments. Statistical analysis for assess-
ing significant differences among multiple groups was done
with one-way ANOVA, followed by a Tukey-Kramer multi-
ple comparisons test (Graph Pad InStat Software; Graph Pad
Inc., San Diego, CA). For comparison between two groups,
Student’s t test was used. Differences were considered signif-
icant at values of p  0.05.
RESULTS
Lcn2 Induces Cardiomyocyte Apoptosis—We first used a
TUNEL assay to detect DNA fragmentation and showed that
more apoptotic cells were evident after treatment of H9c2 cells
with 2g/ml recombinant Lcn2 for 48 h (Fig. 1A).We used 1–5
g/ml Lcn2 in this study based upon preliminary experiments
and published data (13). Quantitative analysis of TUNEL-pos-
itive cells demonstrated a significant increase of almost 8-
fold in apoptotic cells after Lcn2 treatment compared with
untreated control (Fig. 1B). This was also observed in primary
neonatal cardiomyocytes (Fig. S1). Because the exposure of
phosphatidylserine on the outer leaflet of the plasma mem-
brane is one of the earliest features of apoptosis, we used
annexin V (AV) to detect phosphatidylserine in intact cells.
Simultaneously, cell-permeable propidium iodide (PI) was used
to stain the nucleus, and apoptotic cells were analyzed further
using this double staining with AV and PI, followed by flow
cytometry. An increased population of AV/PI cells, indicat-
ing an early stage of apoptotic cells, was observed after 1 g/ml
Lcn2 treatment for 16 h (Fig. 1C). After quantification of data
from three independent experiments, we found that the num-
ber of AV/PI cells, but not AV/PI, was significantly
increased after Lcn2 treatment compared with untreated con-
trols (Fig. 1D).
Lcn2 Increases Caspase-3 Cleavage and Activity—We next
investigated whether caspase-3 cleavage is increased by Lcn2.
First, H9c2 cells were treated with 1g/ml Lcn2 for 16 h before
fixation and immunofluorescent detection of cleaved caspase-3
using a specific antibody (Asp-175). We found that Lcn2
induced cleavage of caspase-3 (Fig. 2A), and quantitative anal-
ysis showed that the number of cleaved caspase-3-positive cells
was significantly increased by 	8-fold (Fig. 2B). Importantly,
the increased cleaved caspase-3 was also observed in neonatal
rat cardiomyocytes exposed to 1 and 2g/ml Lcn2 for 24 h (Fig.
2, C and D). Lcn2-induced caspase-3 cleavage was further con-
firmed by Western blotting using an antibody against the
cleaved formof caspase-3.We observed that the level of cleaved
form (17 kDa) of caspase-3 was significantly increased in H9c2
cells after Lcn2 treatment (Fig. 2, E and F). We then directly
measured the activity of caspase-3 using an assay based on
cleavage of a fluorogenic substrate and found that the activity of
caspase-3 was significantly increased in cells exposed to 2
g/ml Lcn2 for 24 h (Fig. 2G).
Lcn2 Leads to Disruption of Mitochondrial Membrane
Potential—The disruption of mitochondrial membrane poten-
tial is characteristic of intrinsic cellular apoptosis and plays an
important role in the activation of caspase-3. The integrity of
the mitochondrial membrane was measured here by MitoShift
assay using TMRE dye. In control cells, the dye was located in
themitochondria and appearedmainly as punctate red fluores-
cence (Fig. 3). However, the dye relocates upon disruption of
mitochondrial membrane and appeared as more diffuse and
weaker fluorescence in the cytoplasm of cells after 1, 2, and 4
FIGURE 1. Determination of apoptotic cells after Lcn2 treatment. A, apoptotic cells were examined using TUNEL assay for DNA fragmentation. H9c2 cells
were photographed by fluorescence microscopy (magnification, 20) at 48 h after 2 g/ml Lcn2 treatment. Cells treated with buffer not containing Lcn2
(Control) were used for comparison. TUNEL-positive nuclei are shown in green, total nuclei stained with DAPI in blue. B, quantitative analysis (percentage of
apoptotic cells versus total) is shown inhistogram(*,p0.01).C, afterdouble staining, theAVandPI cellswereanalyzedby flowcytometry (left panel, control
cells; right panel, Lcn2-treated cells).D, quantitativedeterminationof data fromFACSanalysis showing treatmentof Lcn2 (1g/ml) for 16helicited a significant
increase in the number of cells undergoing apoptosis (AV/PI) (n
 3; *, p 0.05).
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g/ml Lcn2 treatment for 24 (data not shown) and 48 h (Fig.
3A). Quantitative analysis of fluorescence units of TMRE dem-
onstrated a significant decrease in Lcn2-treated cells (Fig. 3B).
A similar disruption of mitochondrial membrane potential was
also observed in primary neonatal cardiomyocytes (Fig. S2, A
and B).
Lcn2 Stimulates Bax Translocation to Mitochondria—Bax is
an important proapoptotic factor involved in the intrinsic path-
way of apoptosis and increases the mitochondrial membrane
permeability by translocating and integrating into the mem-
brane. Here, we examined translocation of Bax by first using an
antibody against an epitope in the N-terminal domain of Bax
which is normally obscured and only exposed as Bax changes its
conformation when it integrates into the membrane of mito-
chondria (50). We detected an increase in the endogenous
active form of Bax in H9c2 cells after 1 g/ml Lcn2 treatment
for 16 h (Fig. 4A). In untreated cells, few or no N-terminal Bax
immunofluorescence signals were observed. Lcn2-induced Bax
translocation was also observed in neonatal rat cardiomyocytes
after the treatment of 1 and 2 g/ml Lcn2 for 48 h (Fig. 4B). To
further examine and confirm the translocation of Bax, we tran-
siently transfected GFP-Bax into H9c2 cells followed by 1 or 2
g/ml Lcn2 treatment for 24 h. Mitochondria were then
stained in living cells with MitoTracker dye, allowing analysis
of co-localization with GFP-Bax using confocal microscopy.
We observed a higher extent of GFP-Bax co-localizing with
MitoTracker upon Lcn2 treatment (Fig. 4C). In control, GFP-
transfected, cells distinct signals forMitoTrackerdye andGFP
were observed (Fig. 4C).
Lcn2 Alters Intracellular Iron Levels, Leading to Increase in
Cleaved Caspase-3—It has been shown that iron can mediate
apoptosis in a variety of cell types, and because Lcn2 has the
capability of binding to iron we next examined intracellular
iron levels in H9c2 cells using the cell-permeable fluorescent
probe PG-SK. This probe can be quenched by binding intracel-
lular free iron. Cell treatment with FeSO4 and 2-DPDwas used
as positive and negative controls and clearly showed decreased
and increased levels of fluorescence, respectively (Fig. 5A).
Interestingly, we found by observing segmented confocal
images that the signal of PG-SK fluorescence was attenuated
after 2 g/ml Lcn2 treatment for 24 h (Fig. 5A), indicating an
increase in the level of intracellular iron. We also treated cells
FIGURE 2. Detection of cleaved caspase-3 and its activity. A, H9c2 cells were treated without (Control) or with 1 g/ml Lcn2 for 16 h before immunofluo-
rescent detection (magnification,20) of cleaved caspase-3 (green), and nuclei were strained with DAPI (blue). B, number of cleaved caspase-3-positive cells
was counted fromsix randomly selected fields in each individual experiment, andat least three independent experimentswereperformedandanalyzed (*,p
0.01). C and D, as explained for A and B, except neonatal rat cardiomyocytes exposed to 1 or 2 g/ml Lcn2 for 48 h were used (*, p 0.05). E and F, cells were
treated with 0, 1, 2, or 5 g/ml Lcn2 for 24 h, and total protein was extracted and subjected to Western blotting using an antibody recognizing cleaved
caspase-3.-Actin was used as a loading control. A representative blot is shown (E), and n
 3 experiments are quantitated in F (*, p 0.05).G, H9c2 cells were
treated with 2 g/ml Lcn2 for 24 h, and cell lysates were assayed for caspase-3 activity (n
 3; *, p 0.05).
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with 2-DPD (5mM) for 10min to chelate intracellular iron and
found a strong increase in PG-SK fluorescence (Fig. S3). To
quantitate this phenomenon we used an automated confocal
reader together with Spotfire software analysis to assess PG-SK
fluorescence in a large population of single cells. Fig. 5Bdisplays
the range of intracellular iron levels (mean PG-SK fluores-
cence) in control cells (red) and shows that there was a trend of
decreased fluorescence in a significant number of Lcn2-treated
cells (green). A small number of FeSO4-treated cells (yellow)
were used to validate this quantitative approach. Fig. 5C shows
a representative analysis where the number of cells analyzed in
each treatment is shown (Count), and the median fluorescent
intensity was changed from 2859 (Control) to 1754 after treat-
ment of cells with Lcn2. The number of outliers in each case is
very small relative to the total number of cells analyzed (1%).
These data indicate that Lcn2 increased intracellular iron in
cardiomyocytes overall, but not in all cells, which led us to
determine whether there was a direct functional significance of
this change. Using immunofluorescent staining with an anti-
body specific to cleaved caspase-3 in combination with PG-SK
analysis, we confirmed that individual cells exhibiting
decreased PG-SK fluorescence after Lcn2 treatment also
showed an increase in cleaved caspase-3 (Fig. 6A). Upon tem-
poral analysis of treatment with Lcn2 up to 24 h, we observed
that changes in PG-SK fluorescence preceded an increase in
cleaved caspase-3. This suggests that changes in intracellular
ironmaymediate subsequent apoptotic events. To confirm the
mechanistic role of altered intracellular iron levels we next
FIGURE 3. Assessment of mitochondrial membrane potential in H9c2
cells.A, cellswere treatedwith1, 2, and4g/ml Lcn2 for 48handanalyzedby
confocal microscopy (magnification,40) using TMRE dye, with total nuclei
identified using Hoechst 33342. B, quantitative analysis of relative fluores-
cence intensity is shown (n
 4; *, p 0.01).
FIGURE 4. Detection of Bax translocation to mitochondrial membrane in response to Lcn2. A and B, H9c2 cells (A) or primary cardiomyocytes (B) were
treated with or without 1 or 2g/ml Lcn2 for 16 h followed by detection of N-terminal Bax epitope (red), which is only detectable once the protein is inserted
in mitochondrial membrane, with nuclei detected using DAPI. Representative images of n
 3 experiments in each case are shown (magnification,20). C,
H9c2 cells were transiently transfected with GFP-Bax or GFP (Control), followed by treatment with 2 g/ml Lcn2 for 24 h. Mitochondria in live cells were
identified using MitoTracker, in combination with nuclei staining using Hoechst 33342 and examined by confocal microscopy (magnification,63). Repre-
sentative images of n
 3 experiments are shown.
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examined iron-induced apoptosis directly by detecting cleaved
caspase-3 usingWestern blotting.We found that the treatment
of 100 M FeSO4 indeed resulted in an increase of cleaved
caspase-3 in a time-dependent manner in H9c2 cells (Fig. 6B).
Conversely, when we depleted intracellular iron in neonatal rat
cardiomyocytes using the iron chelator 2-DPD we observed
that Lcn2-induced caspase-3 cleavage was attenuated (Fig. 6C).
This phenomenon was further confirmed by showing that
2-DPDpretreatment decreased the ability of Lcn2 to cause Bax
translocation to mitochondria (Fig. 6D). The involvement of
altered intracellular iron levels in apoptosis was also observed
in H9c2 cells (Fig. S4).
Lcn2 Plays Important Physiological Role in Inducing Car-
diomyocyteApoptosis—Wenext performed studies inmice that
were administered recombinant Lcn2, and we observed that
after 14 days an increased number of apoptotic cells were
detected in heart sections by TUNEL and DAPI staining (Fig.
7A). The number of TUNEL-positive cells in wild-type mice
was, as expected, very low (0.5%), and this was increased sig-
nificantly to almost 4% after 14 days of Lcn2 treatment (Fig. 7B).
The circulating Lcn2 level was confirmed by ELISA to be
increased at 14 days of treatment to (7.19  0.92 g/ml com-
pared with 3.98  0.18 g/ml in PBS-injected mice). We also
examinedmacrophage infiltration (CD68 staining) in heart sec-
tions as a measure of inflammation and found that Lcn2
induced an inflammatory response in the heart after 14 days
administration (Fig. 7, C and D). Analysis of cardiac structure
and function by echocardiography at 14 days indicated that
Lcn2-treated mice showed a trend toward decreased left ven-
tricular end systolic and diastolic volumes and increases in frac-
tional shortening, E velocity, heart rate, and cardiac output
(Table 1).
DISCUSSION
Emerging data indicate that circulating levels of Lcn2 corre-
late positively with various aspects of the metabolic syndrome
(10).Work to date has focused principally on the proinflamma-
tory and metabolic effects of Lcn2 (11, 13, 51–53), yet less is
known regarding cardiovascular effects. Several studies have
now shown that Lcn2 was elevated during ischemia-reperfu-
sion processes and in coronary heart disease and myocardial
infarction (12, 20, 21, 23). Here, we analyzed the effect of Lcn2
on cardiomyocyte apoptosis, an important component of car-
diac remodeling leading to heart failure (24, 25).
Our data using FACS analysis of annexin V binding to phos-
phatidylserine, TUNEL staining, and various measures of
caspase-3 activation clearly demonstrate that recombinant
Lcn2 induced apoptosis in primary neonatal cardiomyocytes
and H9c2 cells. Because this is a novel observation and little is
known about Lcn2 signaling we next investigated potential
mechanisms responsible for Lcn2-induced apoptosis. Our
studies uncovered an initially unexpected and novel mecha-
FIGURE 5.Determination of intracellular iron level using PG-SK. A, intracellular free iron levels were monitored in H9c2 cells treated with 2g/ml Lcn2 for
24 h, using the cell-permeable fluorescent dye PG-SK, which is quenched upon binding iron. Treatment of FeSO4 (100 M) was used as positive control. The
images shown are representative segmented images from automated confocal microscopy analysis. B, intensity of fluorescent signal/cell was measured and
analyzed cell by cell in populations treated without or with Lcn2 or FeSO4, and distribution of values is shown here. C, quantitative analysis of cell by cell data
is shown for each condition with number of cells, median fluorescence, and number of outlying values shown.
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nism that integrates the ability of Lcn2 to regulate intracellular
iron levels with known proapoptotic effects of iron. Although
playing a vital role in cellular functions, such as enzyme
activity, intracellular iron levels must be carefully regulated
because iron, especially ferrous (Fe2) form, has high poten-
tial to cause toxicity. The Haber-Weiss (Fenton) reaction,
catalyzed by ferrous iron, generates hydroxyl radicals. Gen-
eration of reactive oxygen species is thus one way in which
increased intracellular ferrous iron has been proposed to
induce apoptosis (54). It was also shown recently that iron
enhanced doxorubicin-induced cardiomyocyte apoptosis
which was prevented by iron chelation using dexrazoxane,
likely via preventing iron-mediated degradation of hypoxia-
inducible factors (55). Iron nanoparticles have also been
shown to enhance the apoptotic effects of 7-ketocholesterol
in cardiomyocytes (56). In general, iron distribution must be
FIGURE 6. Involvement of changing intracellular iron levels in apoptosis. A, intracellular iron was detected by PG-SK and cleaved caspase-3 by immuno-
fluorescence to demonstrate that cells within a population responding to Lcn2 (2 g/ml, up to 24 h) with increased intracellular iron also exhibited more
cleaved caspase-3 detection in H9c2 cells. Representative images of n
 4 experiments are shown. B, detection of cleaved caspase-3 by Western blotting in
H9c2 cells treatedwith FeSO4 (100M, up to 24 h). A representative image and quantitative analysis of n
 3 experiments are shown. C andD, pretreatment of
neonatal rat cardiomyocytes with 2-DPD (0.05 and 0.5 mM) attenuated the effect of Lcn2 on the induction of cleaved caspase-3 immunofluorescence (C) and
immunofluorescent detection of N-terminal Bax (D) in a dose-dependentmanner. FeSO4 (100M, 24 h) was used as positive control (magnification,20), and
quantitativedata (insets) represent four experiments (n
4; *,p0.05,Lcn2 versusLcn2 in the absenceof 2-DPD; #,p0.05,Lcn2without 2-DPD versus
Lcn2 with 0.5 mM 2-DPD).
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tightly regulated due to the high potential of iron for induc-
ing biological toxicity (57, 58).
Lcn2 has the capability to bind iron, and the complex can
internalize through binding to two potential Lcn2 receptors,
24p3R and/or megalin (34, 59). We used PG-SK dye which is
quenched by binding iron, especially ferrous form, and showed
that Lcn2 treatment of cardiomyocytes resulted in a decrease of
PG-SK fluorescence, indicating an increase of intracellular iron
pool. We also confirmed that increasing intracellular iron with
FeSO4 induced cardiomyocyte apoptosis and that chemical
chelation of free intracellular iron attenuated Lcn2-induced
caspase-3 activity. This is in keeping with the literature cited
above showing an important role for iron in cardiomyocyte
apoptosis (54–56). One study suggested that treatment of the
atrial derived HL-1 cell line with recombinant enterobactin-
Fe3 loaded or iron-free Lcn2 protein showed no apoptosis
induction (23). However, it may be that ferrous iron is impor-
tant in mediating the proapoptotic effects of Lcn2. Interest-
ingly, although the average intracellular iron level increased in
the cell population treated by Lcn2, cell by cell image analysis
indicated that the effect was more pronounced in a subpopula-
tion of cells. We therefore examined whether individual cells
showing the most pronounced increase in intracellular iron
showed an increase in cell death. Indeed, decreased PG-SK
fluorescence correlated well with cleaved caspase-3 immuno-
reactivity in individual cells. Because iron has multiple roles in
health and disease (57, 58) our observations on a mechanistic
role for iron in proapoptotic effects of Lcn2 may have more
widespread, and thus far unappreciated, implications in under-
standing additional physiological effects of Lcn2 (10).
Further investigation of the intracellular mechanisms of
Lcn2-induced cardiomyocyte apoptosis demonstrated activa-
tion of the intrinsic apoptotic pathway. In particular, we used
several approaches to demonstrate Bax translocation to the
mitochondrial membrane, a subsequent disruption of mito-
chondrial membrane potential, and caspase-3 activation. This
is in keeping with published work showing that FeSO4 induced
mitochondrial damage leading to nuclear DNA condensation
and fragmentation (32). It has also been shown that iron
induced mitochondrial damage and caused caspase-3 activa-
tion, NF-B induction, and decreased Bcl-2 expression (32).
Here, we also confirmed that increasing intracellular iron with
FeSO4 induced cardiomyocyte apoptosis and that chemical
chelation of free intracellular iron attenuated Lcn2-induced
Bax translocation to mitochondria.
To investigate the physiological significance of our observa-
tions we then conducted in vivo studies in mice administered
Lcn2 for 14 days. Good rationale for these studies also comes
from the fact that iron accumulation has been identified as an
important mediator of age-associated cardiac apoptosis and
proposed as an effective pharmacologic target for therapeutic
intervention (37). Analysis of TUNEL-positive cells showed a
characteristic low value in wild-type mice of 0.5%, but this
was significantly increased in animals treated with Lcn2, thus
confirming translation of our cell-based studies to an animal
model. We analyzed functional parameters in the heart and
found that Lcn2 administration tended to induce an unex-
pected improvement in cardiac function. However, it is impor-
tant to note that Lcn2 also promotes an acute inflammatory
response, as we observed here via CD68 immunofluorescence
tomonitor macrophage infiltration. It is known that inflamma-
tion can induce intracardiac volume depletion, inducing more
rapid heart rate and reduced size of cardiac chambers. Addi-
tional effects of Lcn2, such as changes in cardiac metabolism,
which are still unknown, may also contribute to functional
parameters we measured here using echocardiography. Thus,
our study indicated an early compensatory stage of cardiac
remodeling in the face of elevated apoptosis and inflammation.
The temporal nature of cardiac remodeling events is highly sig-
nificant (5), and this is also likely to be the case for Lcn2-medi-
ated changes. It will be of interest to perform more chronic
studies and assess long term changes in cardiac remodeling
induced by Lcn2 and whether cardiac iron content is increased
in such animals. Indeed, iron overload is known to cause ele-
FIGURE 7.Determinationof apoptosis and inflammation inheart section.
A and C, mouse heart sections were prepared after 14 days of Lcn2 adminis-
tration, and apoptotic cellswere determinedusing TUNEL assay forDNA frag-
mentation (A) and macrophage infiltration detected by CD68 immunofluo-
rescence (C), with cell nuclei stainedusingDAPI.B andD, quantitative analysis
of multiple field of view of sections from n
 4 nice is shown in histogram (*,
p 0.01 and 0.05 in B and D, respectively).
TABLE 1
Functional parameters derived from echocardiography analysis in hearts frommice treated with Lcn2 or PBS only
Analysis is from six mice and ten mice in control and Lcn2 groups, respectively, and data are presented as mean S.E.
Measurement E velocity Fractional shortening Cardiac output
Left ventricular volume
Heart rateDiastolic Systolic
mm/s % ml/min ml ml beats/min
Control 18.12 0.57 22.43 1.29 12.28 1.12 63.25 2.60 33.40 2.83 393.09 9.29
Lcn2 24.39 1.26a 27.19 1.94a 14.73 0.70a 64.02 2.25 28.56 2.19 405.86 11.05
a p 0.05 (Lcn2 vs. control).
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vated oxidative stress, myocardial apoptosis, systolic and dia-
stolic dysfunction, and increased morbidity (35, 38, 60).
In conclusion, Lcn2-induced cardiomyocyte apoptosis is at
least in part mediated via an increase in intracellular iron levels
and induction of the intrinsic mitochondrial pathway via trans-
location and activation of Bax. Further experiments to under-
stand fully the regulation of various components of cardiac
remodeling by Lcn2 and the long term consequences of such
changes in vivo will now be of great interest.
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